Nashat Imran, MD
Nephrology · Detroit, MINPI 1376798199
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,725 of the $2,268 with a category attached, or 76.1%. Vifor Pharma, Inc. accounts for 81.5% of it on its own, with 7 other manufacturers making up the rest. 2021 is the largest year on record at $1,725, 3.3 times the $527 reported in 2019.
Across 27 payments — averaging $84.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$196
- AstraZeneca$68
- Outset Medical Inc$47
- Amgen$44
- Intercept Pharmaceuticals, Inc.$26
- plus $38 from 2 others
What the payments were for
- Speaking & faculty fees$1,72576%
- Food & beverage$54024%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 7 | $1,850 |
| Otsuka America Pharmaceutical, Inc. | 8 | $196 |
| AstraZeneca(2 entities) | 4 | $68 |
| Outset Medical Inc | 2 | $47 |
| Amgen | 3 | $44 |
| Intercept Pharmaceuticals, Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,268 in reported general payments places this provider in the 70th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 25 | $6,563 |
| Valsartan | 21 | $649 |
| Losartan Potassium | 36 | $312 |
| Carvedilol | 15 | $147 |
| Amlodipine Besylate | 13 | $76 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Detroit
- Anatole BesarabDetroit$102K
- Kausik UmanathDetroit$85K
- Aris UrbanesDetroit$14K
- Alexander YevzlinAnn Arbor$1.1M
- Muwaffaq SalamehBay City$164K
- Laura MarianiAnn Arbor$150K
- Crystal Gardner-MartinLivonia$140K
- Katherine KwonSaint Joseph$111K
- Richard CrossSaint Clair Shores$96K
- Joel TopfRoseville$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.